HOME >> MEDICINE >> NEWS
Scripps Research Institute group designs DNA vaccine that inhibits growth of cancerous tumors

A group of researchers at The Scripps Research Institute (TSRI) have developed a novel DNA vaccine that helps the body resist the growth of cancerous tumors by choking off the tumors' blood supply.

"We stimulate the immune system to recognize proliferating blood vessels in the tumor vasculature and to recruit killer T cells to destroy these vessels," explains TSRI Immunology Professor Ralph Reisfeld, Ph.D., who conducted the study with Research Associate Andreas G. Niethammer, M.D., and others. "Deprived of its blood supply, the tumor [eventually dies]."

Niethammer, Reisfeld, and their collaborators describe their successful pre-clinical studies with the vaccine in an article to be published next month in the journal Nature Medicine.

Though not yet tested in humans, their vaccine has the potential to treat many types of cancer, and it may provide a new strategy for the rational design of cancer therapies.

Two Approaches to Treating Cancer

Cancer is not a single disease, but rather over a hundred diseases caused by various sorts of mutations inside various cells in various tissues. Some mutations upregulate genes, increasing the expression of metalloproteinases for instance; others downregulate them, shutting off production of receptor proteins.

After certain mutations occur, a cancer cell grows out of control, dividing over and over and forming a solid tumor. Cancer tumors often damage the tissues where they are located and some can metastasize and migrate through the bloodstream--the malignant carcinoma that claims so many lives every year.

In recent years, some novel approaches to treating cancer have generated interest in scientific circles and society at large.

One of these approaches to is to try to block the process of angiogenesis, the formation of new blood vessels that bring necessary nutrients and oxygen to the hungry tumor cells. Block angiogenesis, the thinking goes, and you can
'"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
4-Nov-2002


Page: 1 2 3 4

Related medicine news :

1. Scripps atmospheric scientist appointed to Pontifical Academy of Sciences
2. Chemical turns stem cells into neurons say scientists at Scripps Research Institute
3. Sepsis vaccine proves protective in preliminary studies at The Scripps Research Institute
4. Researchers search for first sign of congestive heart failure
5. Research offers hope of new treatments for liver damage
6. Research suggests possible blood test for multiple sclerosis
7. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
8. 2005 Award for Basic Research in Biological Mineralization
9. 2005 Craniofacial Biology Research Award
10. 2005 Research in Dental Caries Award
11. 2005 Research in Prosthodontics and Implants Award

Post Your Comments:
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc ... Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an ... preparing for the exam easy and painless. MDLinx offers thousands of board-exam style ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According to the article ... floor of the Pasadena courthouse was contained and extinguished by the city’s fire department before ... in the building at the time of the fire, and it was a fire alarm ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Well-known for its ... offering wedding cakes with custom designs, making life just a little bit ... designed wedding cakes for each customer who orders one. , The bakery provides a ...
(Date:7/31/2015)... ... , ... Cosmetic Town has proven itself as the leader ... procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. The ... , Staying up to date with the latest cosmetic trends has never ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... a one-day event geared to patients and family members, medical professionals, and researchers, ... regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma Applied ...
Breaking Medicine News(10 mins):Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
(Date:7/31/2015)... SAN DIEGO , July 31, 2015  Eisai ... Ltd. (Headquarters: Tokyo , President and ... Inc. (Headquarters: San Diego, California , ... HALO") have signed a clinical collaboration agreement to evaluate ... in combination with Halozyme,s investigational drug PEGPH20 (PEGylated recombinant ...
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)... 2015  ResMed Inc. (NYSE: RMD ) today ...  Revenue for the quarter was $453.1 million, a 9 ... 2014 (a 17 percent increase on a constant currency ... quarter ended June 30, 2014.  Diluted earnings per share ... ended June 30, 2014.  The results ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
Cached News: